Catalent, Inc. Common Stock (NY:CTLT)

63.48 UNCHANGED

Last Price Updated: 7:00 PM EST, Dec 17, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Catalent, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks ↗

February 06, 2024

Thanks to weight loss and obesity drugs, Eli Lilly and Novo Nordisk could become the first trillion-dollar stocks in the pharma industry.

Via InvestorPlace

Catalent Analysts Raise Their Forecasts Following Acquisition News ↗

February 06, 2024

On Monday, Catalent, Inc. (NYSE: CTLT) announced it will be acquired by Novo Holdings. Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash.

Via Benzinga

Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 06, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Why Catalent Stock Soared Today ↗

February 05, 2024

Catalent has agreed to be acquired by Novo Nordisk's parent company.

Via The Motley Fool

Why Novo Nordisk Stock Crushed the Market on Monday ↗

February 05, 2024

The pharmaceutical giant will receive three manufacturing facilities from its parent company's latest acquisition.

Via The Motley Fool

Analyst Expectations For Catalent's Future ↗

January 25, 2024

Via Benzinga

What Happened With Caltalent Stock? ↗

December 19, 2023

Catalent, Inc. (NYSE: CTLT) shares traded higher on Tuesday. Following losses at the end of October, the stock has rebounded over the past month.

Via Benzinga

What 9 Analyst Ratings Have To Say About Catalent ↗

November 16, 2023

Via Benzinga

Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday? ↗

February 05, 2024

Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for...

Via Benzinga

Topics Economy

Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record ↗

February 05, 2024

Amgen is looking to rival Eli Lilly and Novo Nordisk in weight-loss drugs.

Via Investor's Business Daily

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

February 05, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 05, 2024

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS...

Via Benzinga

What's Going On With Eli Lilly Stock Today? ↗

February 05, 2024

Eli Lilly's stock surge, driven by the upcoming Q4 2023 results and the impact of FDA-approved weight-loss drug Zepbound.

Via Benzinga

Catalent (CTLT) Stock Pops 10% on Sale to Novo Nordisk ↗

February 05, 2024

Catalent stock is rising higher on Monday after the company announced a $16.5 billion cash acquisition deal for CTLT shares.

Via InvestorPlace

Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday ↗

February 05, 2024

U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday.

Via Benzinga

Topics Stocks

Ozempic Maker Strikes $11B Deal With Catalent As It Rushes To Meet Massive Weight-Loss Drug Demand ↗

February 05, 2024

This move comes on the heels of the company's recent collaborations to develop new treatment approaches for obesity management and chronic liver diseases.

Via Benzinga

SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Catalent; Is $63.50 a Fair Price?

February 05, 2024

From Johnson Fistel, LLP

Via Business Wire

CTLT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Catalent, Inc. Is Fair to Shareholders

February 05, 2024

From Halper Sadeh LLC

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

February 05, 2024

The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning!

Via InvestorPlace

Novo Holdings to Acquire Catalent

February 05, 2024

From Catalent, Inc.

Via Business Wire

Catalent, Inc. Announces Second Quarter Fiscal Year 2024 Earnings Conference Webcast

January 26, 2024

From Catalent, Inc.

Via Business Wire

Catalent Commits to Reducing Greenhouse Gas Emissions by 2030

January 25, 2024

From Catalent, Inc.

Via Business Wire

S&P 500 Shatters Records: The Top-Performing Stocks In January 2024 ↗

January 19, 2024

2023 was a historical milestone for S&P 500 as it once again surpassed record highs, largely due to tech giants and artificial intelligence. Top gainers were NVIDIA, Meta Platforms, and AMD.

Via Benzinga

Topics Artificial Intelligence Stocks

These 9 Stocks Are Running To Start 2024 ↗

January 14, 2024

The S&P 500 is up just 0.2% in 2024. These stocks are off to a strong start.

Via Investor's Business Daily

Topics Stocks

Catalent, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 04, 2024

From Catalent, Inc.

Via Business Wire

Catalent Announces Closing of Incremental Term Loans

December 19, 2023

From Catalent, Inc.

Via Business Wire

Catalent Regains Compliance with NYSE Continued Listing Standards

December 15, 2023

From Catalent, Inc.

Via Business Wire

Jim Cramer: Buy This Financial Stock, 'I Think They're High Quality' ↗

November 30, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vishay Intertechnology, Inc.

Via Benzinga

Intel To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 16, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy ↗

November 15, 2023

Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.